March 2026 in “Frontiers in Pharmacology” Exprecell™ is as effective as traditional methods but produces more f-PRF and is simpler to use.
1 citations
,
April 2010 in “Expert Review of Dermatology” The document concludes that early diagnosis and treatment are crucial for managing rare hair loss disorders and that more research is needed to improve treatment strategies.
Scalp involvement in primary cutaneous lymphomas is common and can be aggressive, requiring careful attention.
Collagen CLR and placenta extract may help treat diffuse hair loss.
March 2026 in “Trends in Sciences” PRF and CGF are becoming more popular than PRP in regenerative medicine due to their simplicity and lack of additives.
June 2025 in “Dermatologic Surgery” GFC improves hair quickly, while PRP offers longer-lasting benefits; using both sequentially is recommended.
March 2025 in “OncoTargets and Therapy” A specific genetic trait in tumor cells is linked to longer survival without disease in certain lymphoma patients.
7 citations
,
June 2017 in “Journal of Cutaneous Pathology” Cystic panfolliculoma resembles hair follicle tumors due to specific cell interactions.
49 citations
,
January 2003 in “Clinical and Experimental Dermatology” The document concludes that post-menopausal frontal fibrosing alopecia is a poorly understood condition that does not respond well to common treatments.
May 2024 in “Journal of the Egyptian Women's Dermatologic Society /Journal of the Egyptian Women's Dermatologic Society” Combining fractional CO2 laser and PRP is very effective for treating female hair loss.
January 2014 in “Journal of Central South University(Science and Technology)” PPCM microspheres can effectively release finasteride over 42 days.
16 citations
,
September 2018 in “Journal of Molecular Liquids” The PS-b-PAA copolymer nanomicelles are effective for delivering a cancer treatment drug in photodynamic therapy.
14 citations
,
August 2015 in “Endocrinology” The antibody 005-C04 blocks prolactin receptors, causing reversible infertility, impaired lactation, and hair regrowth in female mice.
2 citations
,
May 2021 in “Clinical Pharmacology in Drug Development” Clascoterone is safe for the heart, even at high doses.
July 2023 in “British journal of dermatology/British journal of dermatology, Supplement” Skin tumors with CYLD cutaneous syndrome show more NF-κB activity and less organized collagen.
1 citations
,
October 2022 in “Current Opinion in Endocrinology, Diabetes and Obesity” Female pattern hair loss is common in women with polycystic ovarian syndrome.
June 2023 in “British Journal of Dermatology” Coinheritance of BRCA2 and CYLD genes may lead to new treatment options for certain cancers.
September 2022 in “British Dental Journal” Platelet-rich fibrin is becoming popular for medical and cosmetic uses like hair growth and natural fillers.
April 2018 in “Journal of Investigative Dermatology” CENPV, a new partner of CYLD, helps regulate ciliary acetylated tubulin and is overexpressed in certain skin tumors.
32 citations
,
August 1982 in “Journal of the American Academy of Dermatology” GLPLS and LPP are variants of lichen planus.
89 citations
,
February 2002 in “Australasian journal of dermatology” A premenopausal woman had hair loss and skin issues, treated with topical steroids.
23 citations
,
August 1983 in “PubMed” Clq deficiency is linked to systemic lupus erythematosus symptoms.
April 2019 in “Journal of Investigative Dermatology” Frontal Fibrosing Alopecia involves disrupted cholesterol pathways, fibrosis, and increased mast cells.
30 citations
,
September 2013 in “PubMed” Chinese women with PCOS and a BMI of 24 or higher should be screened for fatty liver disease.
Lichen planopilaris and frontal fibrosing alopecia are likely the same disease with different clinical appearances.
1 citations
,
November 2025 in “International Journal of Clinical Pharmacy” Cladribine has known risks and potential new safety concerns, requiring careful monitoring.
October 2023 in “Journal of the American Academy of Dermatology” Clascoterone cream could be used for other skin conditions affected by hormones.
Excluding alopecia and mucous membrane components from the CLASI-A score reduces its effectiveness in capturing important disease activity.
19 citations
,
July 2022 in “PNAS Nexus” Similar treatments might work for different types of scarring hair loss.
52 citations
,
March 2007 in “Dermatologic Therapy” The CLASI is a reliable tool for measuring the severity of cutaneous lupus erythematosus.